Neurotransmitter Systems and Receptor Dynamics in Depression: Pathophysiology and Therapeutic Perspectives

Ms. Ankita Chandrakant Shinde[1], Kature Vaibhav Rajaram [2], Vraj R. Patel [3]
Ms. Namita Sunil Sagavekar[4], Shivam Pal [5], Sakshi Govinda Badgujar [6]
[1]*Lecturer, New College of Pharmacy, Kolhapur, India*
[2]*Student, Sharadchandra Pawar College of Pharmacy, Otur, Pune, India*
[3]*Student, Department of Pharmaceutics, Parul University, India*
[4]*Assistant Professor, Department of Pharmaceutics, Parul University, India*
[5]*Assistant Professor, Ghausia College of Pharmacy, Kashmiripur, Deomai, Fatehpur, India*
[6]*Student, MET's Institute of Pharmacy, Nashik, India*

***Abstract*—Depression isn't just about feeling down. It's a tough mental health condition that hangs around, draining your energy and making it hard to think straight. Your quality of life takes a big hit. Underneath it all, the chemicals in your brain start to slip out of balance. Key players like serotonin, norepinephrine, dopamine, and glutamate—important for keeping your mood steady, helping your brain adapt, and even growing new brain cells—just stop working as a team. When their receptors (like 5-HT1A, NMDA, AMPA, and adrenergic receptors) start acting up, everything gets worse. But that's not the end of the story. The body's main stress system, the HPA axis, also goes off course. Add on chronic brain inflammation and oxidative stress, and these brain signals get even more tangled.**

Research keeps showing that chronic stress, your genes, and slow-building chemical changes all push these problems forward. They reshape key areas in your brain—the prefrontal cortex, hippocampus, and amygdala—leading to lasting changes in how you feel and act. To fight back, doctors use medications like SSRIs, SNRIs, atypical antidepressants, and drugs aimed at NMDA receptors. The idea is to bring those brain chemicals back into balance. But the truth is, these treatments don't always do the trick. Many people never get the relief they need. That's why scientists are chasing new options—fast-acting drugs like ketamine, therapies involving psychedelics, and even brain stimulation.

This review gets into how all these things are mixed together—how neurotransmitters and their receptors spiral out of sync, and the new treatments out there aiming to untangle them. If you want anything explained more or have questions, just let me know.

***Index Terms*—Depression; Major Depressive Disorder (MDD); Neurotransmitter Systems; Receptor Dynamics; Serotonin; Dopamine; Glutamate; Neuroplasticity; Antidepressants; Therapeutic Targets.**

I. INTRODUCTION

Depression affects millions of people worldwide and stands out as one of the most disabling mental disorders out there. It drags people down with lasting sadness, loss of interest in things they once liked, trouble thinking, and even physical complaints that make daily life much harder. According to the World Health Organization, depression is the leading cause of disability across the globe. It weighs heavily not just on individuals, but on families, communities, and the larger economy.



What actually causes depression? It's not just one thing—genes, life experiences, and how the brain works all play a part, tangled together in complex ways. Out of all these, changes in neurotransmitter systems and their receptors really drive the development and persistence of depression. Brain chemicals like serotonin, norepinephrine, dopamine, and glutamate help control mood, brain flexibility, and how brain circuits connect. When something's off in these systems, signals between neurons get mixed up, receptor sensitivity shifts, and even the structure of brain areas—like the prefrontal cortex, hippocampus, and amygdala—can change. Beyond neurotransmitters, problems in the HPA axis (which controls stress hormones), chronic inflammation in the brain, oxidative stress, and loss of neurotrophic factors also come into play. All these lead to nerve cell shrinkage, fewer new neurons growing, and neural networks going haywire, which shows up as the typical symptoms of depression.

Understanding what's actually happening in the brain isn't just interesting science; it helps us target treatments that really work. Most current antidepressants—SSRIs, SNRIs, and atypical options—focus on restoring balance in neurotransmitter systems. Still, they don't work for everyone, and there's often a frustrating wait before improvements kick in. This pushes researchers to look for new answers, like fast-acting drugs (ketamine, for example), therapy guided by psychedelics, or brain stimulation techniques.

This review will dive into how messed-up neurotransmitter signaling and receptor activity connect to the cutting edge of depression treatment, both with medications and other therapies. By digging into these mechanisms, we can get a clearer view of what's happening in depression and, hopefully, improve life for people dealing with it.

II. NEUROTRANSMITTERS IN DEPRESSION

When it comes to depression, things get messy with our brain's neurotransmitter systems—those chemical messengers that affect everything from mood to memory. Shifts in neurotransmitter levels, messed-up receptors, or changes in how neurons connect all play a part in the way depressive symptoms show up. Let's look at some of the main players behind all this.

2.1 Serotonin (5-HT) System

Serotonin gets the most attention in depression research, and for good reason. This neurotransmitter—sometimes called 5-HT—helps keep our moods steady, emotions in check, and our thinking sharp. When serotonin levels drop, when the serotonin transporter (SERT) doesn't work right, or when the serotonin receptors start misbehaving, depression can settle in.



Two serotonin receptors stand out:



- If the 5-HT1A receptor stops working properly, you see issues with mood swings, increased anxiety, and folks get a lot jumpier about stress.
- On the flip side, when the 5-HT2A receptor goes into overdrive, people become more emotionally up-and-down, and their thinking gets worse.

Medications like fluoxetine and sertraline—better known as SSRIs—try to fix this by stopping serotonin from being reabsorbed too quickly, so more hangs out in the synapses. And yes, these drugs boost the serotonin signal, but relief takes a while to kick in. That makes people wonder if something else is also at play beyond the extra serotonin.

2.2 Norepinephrine (NE) System

Norepinephrine, or NE, runs the show when it comes to energy, alertness, and handling stress. It's essential for how the prefrontal cortex works, plus the limbic system and hippocampus—basically, all the emotional control centers in the brain. In depression, when NE drops or its receptors don't work right, people feel drained, can't focus, and just go emotionally numb.

Some key receptors tied to NE:

- The α2-adrenergic receptors (found presynaptically) control how much NE gets released. If these go into overdrive, NE levels tank.
- β1-adrenergic receptors tie directly to mood, and when they're less active, depression gets worse.
- β2-adrenergic receptors help people handle stress better and bounce back emotionally.

Drugs like venlafaxine and duloxetine, which are SNRIs, crank up both serotonin and norepinephrine signals. Norepinephrine reuptake inhibitors (NRIs), like reboxetine, focus on boosting NE and can help restore energy and motivation.

2.3 Dopamine (DA) System

Dopamine drives our reward system, motivation, and the sheer enjoyment of life. When the mesolimbic and mesocortical pathways don't work right, people start losing interest in things they once loved, their motivation tanks, and thinking clearly gets tough—classic issues in depression.



What's going on at the receptor level? In depression, you'll see less D1 receptor activity, which makes it harder to adapt and stay motivated. D2 receptors don't function well either, so rewards feel flat and emotions just don't hit the same. D3 receptors play a part too—they usually boost your drive and goal-setting, but they're not firing properly in depression.

Some antidepressant medications aim at this dopamine system, like bupropion. It ramps up dopamine transmission by stopping its reuptake along with norepinephrine. There's ongoing work with dopamine agonists and modulators, especially for folks who don't get better with standard treatments.

2.4 Glutamate System

Lately, researchers are seeing the glutamate system—especially how it handles synaptic connections and nerve cell health—as a big piece of the depression puzzle. Balance between excitatory (glutamate) and inhibitory (GABA) signals is essential for the brain to function smoothly.

Depression throws this balance off in a few ways. Too much activity at NMDA receptors makes things toxic, damaging neurons. AMPA receptors, meanwhile, aren't working as they should, so the brain's ability to adapt and form new connections drops. Changes in metabotropic glutamate receptors (mGluRs) also make it tougher to handle stress and regulate emotions.

Ketamine, which blocks NMDA receptors, is making waves because it brings on fast and lasting antidepressant effects. This has shifted thinking—now, modulating the glutamate system looks like a promising direction for tackling treatment-resistant depression.

So, that's how neurotransmitter imbalances can drive depression, and why treatments target these systems to try to tip the balance back.

III. NEUROTRANSMITTER RECEPTORS AND DEPRESSION

Neurotransmitter receptors are specialized proteins located on neuronal membranes that mediate the effects of neurotransmitters and regulate neuronal communication. Alterations in receptor density, sensitivity, and signaling pathways can disrupt neurotransmission, contributing to the development and progression of depression. Understanding receptor dynamics is essential for identifying therapeutic targets and developing effective antidepressant treatments.

3.1 Serotonin Receptors

Serotonin (5-hydroxytryptamine; 5-HT) is a critical neurotransmitter involved in the regulation of mood, emotion, cognition, sleep, and stress responses. Dysfunction of serotonergic receptors has been

strongly implicated in the pathophysiology of depression.

3.1.1 5-HT1A Receptors

The 5-HT1A receptor is one of the most extensively studied serotonin receptor subtypes in depression. These receptors are abundantly expressed in the hippocampus, prefrontal cortex, amygdala, and raphe nuclei.

Importance in Depression:

1. Regulate mood, emotional processing, and stress resilience.
2. Activation of postsynaptic 5-HT1A receptors produces anxiolytic and antidepressant effects.
3. Reduced receptor density or impaired signaling has been associated with depressive symptoms and increased vulnerability to stress.
4. Genetic variations affecting 5-HT1A receptor expression may increase the risk of depression.

Therapeutic Significance:

1. Selective serotonin reuptake inhibitors (SSRIs) enhance serotonergic neurotransmission and indirectly stimulate 5-HT1A receptors.
2. Drugs such as Buspirone act directly on 5-HT1A receptors and may improve depressive and anxiety symptoms.
3. Enhancement of 5-HT1A receptor function is considered an important mechanism underlying antidepressant efficacy.

3.1.2 5-HT2A Receptors

5-HT2A receptors are widely distributed throughout the cerebral cortex, limbic structures, and other brain regions involved in cognition and emotional regulation.

Importance in Depression:

1. Modulate mood, cognition, perception, and emotional processing.
2. Excessive activation of 5-HT2A receptors has been associated with anxiety, emotional dysregulation, and depressive symptoms.
3. Altered receptor expression and signaling may contribute to cognitive impairment commonly observed in depression.

Therapeutic Significance:

1. Antagonism or modulation of 5-HT2A receptors can improve mood, sleep quality, and cognitive function.
2. Several atypical antipsychotics, including Quetiapine, exert antidepressant effects partly through 5-HT2A receptor blockade.
3. Emerging psychedelic therapies act through 5-HT2A receptors and have demonstrated rapid antidepressant potential in treatment-resistant depression.

3.1.3 Other Serotonin Receptors

Additional serotonin receptor subtypes also contribute to depression and antidepressant responses:



1. 5-HT1B Receptors: Regulate serotonin release and influence mood-related behaviors.
2. 5-HT3 Receptors: Involved in anxiety, cognition, and emotional regulation; antagonism may enhance antidepressant activity.
3. 5-HT4 and 5-HT7 Receptors: Emerging therapeutic targets that may promote neuroplasticity and accelerate antidepressant responses.
4. 3.2 Adrenergic Receptors

Adrenergic control regulates mood, alertness, and stress. Depressive conditions of fatigue, poor concentration, and emotional liability are linked with adrenergic receptor dysregulation.

3.2 Adrenergic Receptors

The noradrenergic system plays a critical role in regulating mood, attention, arousal, stress responses, and cognitive function. Norepinephrine (NE), primarily synthesized in the locus coeruleus, exerts its effects through adrenergic receptors, including α- and β-receptor subtypes. Alterations in adrenergic receptor function have been strongly associated with depressive disorders, particularly symptoms such as

fatigue, impaired concentration, reduced motivation, and emotional dysregulation.

3.2.1 α2-Adrenergic Receptors

α2-Adrenergic receptors are predominantly located presynaptically as autoreceptors on noradrenergic neurons, where they regulate the release of norepinephrine through a negative feedback mechanism.

Importance in Depression:

Excessive activation of α2 receptors suppresses norepinephrine release, leading to reduced noradrenergic neurotransmission.

→ Decreased norepinephrine availability contributes to symptoms such as lethargy, low energy, diminished motivation, impaired attention, and psychomotor slowing.
→ Dysregulation of α2 receptors has been implicated in stress-related mood disorders and treatment-resistant depression.

Therapeutic Significance:

→ Antagonism of α2 receptors enhances the release of both norepinephrine and serotonin.
→ The antidepressant Mirtazapine exerts its therapeutic effect primarily through α2-adrenergic receptor blockade.
→ Increased monoaminergic neurotransmission resulting from α2 antagonism contributes to improved mood, sleep quality, and emotional well-being.

3.2.2 β1- and β2-Adrenergic Receptors

β-Adrenergic receptors are widely distributed throughout the central nervous system and are involved in regulating mood, cognition, stress adaptation, and emotional processing.

β1-Adrenergic Receptors

a) Predominantly involved in attention, memory formation, and cognitive performance.
b) Contribute to emotional regulation and behavioral responses to environmental stimuli.
c) Reduced β1 receptor signaling may contribute to cognitive impairment and depressive symptoms.

β2-Adrenergic Receptors

a) Play an important role in stress resilience and adaptation to environmental challenges.
b) Influence emotional processing and neural plasticity.
c) Dysregulation may impair stress-coping mechanisms and increase susceptibility to depression.

Therapeutic Significance:

a) Restoration of balanced β-adrenergic signaling may improve mood and cognitive function.
b) Adrenergic receptor modulation remains an important target for the development of novel antidepressant therapies.

3.3 Dopamine Receptors

Dopamine is a key neurotransmitter involved in reward processing, motivation, pleasure, reinforcement learning, and executive function. Dysfunction of dopaminergic neurotransmission is strongly associated with anhedonia, reduced motivation, impaired decision-making, and cognitive deficits, which are hallmark symptoms of major depressive disorder.

3.3.1 D1 and D2 Receptors

D1 and D2 receptors are highly expressed in the mesolimbic and mesocortical pathways, particularly within the prefrontal cortex, nucleus accumbens, and striatum.

Importance in Depression:

a) Regulate reward perception, motivation, cognitive flexibility, and emotional regulation.
b) Reduced D1 and D2 receptor activity diminishes reward sensitivity and decreases responsiveness to pleasurable experiences.
c) Impaired signaling contributes to anhedonia, loss of interest, reduced goal-directed behavior, and cognitive dysfunction.
d) Alterations in D1/D2 receptor-mediated pathways are commonly observed in patients with major depressive disorder.

Therapeutic Significance:

a) Enhancement of dopaminergic neurotransmission may alleviate motivational and cognitive symptoms.
b) The atypical antidepressant Bupropion increases dopamine and norepinephrine signaling, thereby improving energy, motivation, and mood.
c) Dopamine receptor agonists have shown potential benefits in treatment-resistant depression and

depressive symptoms associated with neurodegenerative disorders.

3.3.2 D3 Receptors

D3 receptors are predominantly localized within the mesolimbic reward pathway, especially in the nucleus accumbens and ventral tegmental area (VTA), regions critically involved in motivation and reward processing.

Importance in Depression:

a) Regulate reward anticipation, reinforcement learning, and goal-directed behavior.
b) Dysfunction of D3 receptors has been linked to anhedonia, emotional blunting, and motivational deficits.
c) Reduced D3 receptor activity may impair the ability to experience pleasure and maintain engagement in rewarding activities.

Therapeutic Significance:

a) D3 receptors have emerged as promising targets for novel antidepressant drug development.
b) Selective modulation of D3 receptor signaling may improve motivational deficits and reward-processing abnormalities in depression.
c) Ongoing research is investigating D3 receptor-targeted therapies for treatment-resistant and anhedonic forms of depression.

3.4 Glutamate Receptors

The glutamatergic system is the major excitatory neurotransmitter system of the brain, implicated in synaptic plasticity, learning, and mood regulation. Dysregulation of glutamate receptors has been increasingly shown to be an important mechanism in depression, and especially in treatment-resistant depression.



❖ NMDA (N-Methyl-D-Aspartate) Receptors:

Engaged in synaptic plasticity, learning, and memory. Excessive activation causes excitotoxicity with ensuing neuronal damage and snap to dysfunction, features that are pathogenically pertinent to depression.

Ketamine, an NMDA receptor antagonist, has been found to induce a fast action in triggering an antidepressant effect through the reduction of overactivity of NMDA receptors as well as inducing synaptogenesis.

Other NMDA-modulating drugs (e.g., ketamine, D-cycloserine) are also under investigation for their antidepressant effects.

❖ AMPA (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) Receptors:

Modulate fast excitatory neurotransmission and are important for synaptic plasticity.

AMPA receptor dysfunction is responsible for cognitive impairment and emotional lability in depression.

Ketamine and ampakines (AMPA receptor modulators) are antidepressants that activate AMPA receptors to produce synaptic plasticity and enhance mood and cognition.

In light of new understanding regarding glutamate's role in depression, drug targeting of NMDA and AMPA receptors represents an extremely promising treatment direction, especially in treatment-resistant patients to traditional monoaminergic antidepressants. This addition provides a deeper insight into how glutamate receptor dysfunction contributes to depression and highlights novel treatment approaches. Let me know if you'd like any further refinements!

IV. THERAPEUTIC INSIGHTS AND FUTURE DIRECTIONS

Advances in understanding the neurobiology of depression have significantly influenced the development of antidepressant therapies. Most currently available treatments primarily target monoaminergic neurotransmission; however, emerging therapeutic strategies are expanding beyond traditional approaches to address treatment-resistant depression, improve response rates, and achieve faster therapeutic effects. Novel receptor modulators, glutamatergic agents, neurostimulation techniques,

and personalized medicine approaches represent promising directions in the management of depressive disorders.

4.1 Current Antidepressant Strategies

4.1.1 Selective Serotonin Reuptake Inhibitors (SSRIs)

Selective serotonin reuptake inhibitors (SSRIs) are considered first-line pharmacological treatments for major depressive disorder. These agents inhibit the serotonin transporter (SERT), thereby increasing serotonin concentrations within the synaptic cleft and enhancing serotonergic neurotransmission.

Common SSRIs include:

a) Fluoxetine
b) Sertraline
c) Escitalopram
d) Paroxetine
e) Citalopram

Clinical Significance:

a) Effective for mild to severe depression.
b) Improve mood, anxiety symptoms, and emotional regulation.
c) Generally exhibit favorable safety and tolerability profiles compared with older antidepressants.

4.1.2 Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs inhibit the reuptake of both serotonin and norepinephrine, enhancing neurotransmission in serotonergic and noradrenergic pathways.

Examples include:

a) Venlafaxine
b) Duloxetine
c) Desvenlafaxine
d) Levomilnacipran

Clinical Significance:

a) Particularly useful in patients experiencing fatigue, low energy, impaired concentration, and chronic pain syndromes.
b) Demonstrate efficacy in treatment-resistant and recurrent depression.

4.1.3 Norepinephrine Reuptake Inhibitors (NRIs)

NRIs selectively block norepinephrine reuptake, resulting in increased synaptic norepinephrine availability.

Example:

a) Reboxetine

Clinical Significance:

a) Improve alertness, attention, motivation, and psychomotor activity.
b) May be beneficial in patients with prominent symptoms of lethargy and reduced energy.

4.1.4 Atypical Antidepressants

Atypical antidepressants utilize diverse mechanisms of action that extend beyond conventional monoamine reuptake inhibition.

Bupropion

a) Dopamine–norepinephrine reuptake inhibitor (DNRI).
b) Enhances dopaminergic and noradrenergic neurotransmission.
c) Particularly effective in addressing anhedonia, fatigue, and motivational deficits.

Mirtazapine

a) α2-adrenergic receptor antagonist.
b) Increases both serotonin and norepinephrine release.
c) Also improves sleep quality and appetite.

Clinical Significance:

a) Useful for patients who do not respond adequately to SSRIs or SNRIs.
b) Often selected based on specific symptom profiles and tolerability considerations.

4.1.5 NMDA Receptor Antagonists

The discovery of glutamatergic dysfunction in depression has led to the development of rapid-acting antidepressants targeting N-methyl-D-aspartate (NMDA) receptors.

Ketamine

a) Noncompetitive NMDA receptor antagonist.
b) Produces rapid antidepressant effects, often within hours.
c) Promotes synaptic plasticity and increases brain-derived neurotrophic factor (BDNF) signaling.

Esketamine

a) S-enantiomer of ketamine administered intranasally.
b) Approved for treatment-resistant depression.
c) Demonstrates rapid symptom improvement and reduction in suicidal ideation.

Clinical Significance:

a) Represents a major advancement in depression treatment.
b) Particularly valuable for patients with treatment-resistant depression and acute suicidal risk.

4.2 Future Directions in Depression Treatment

4.2.1 Personalized Medicine and Precision Psychiatry

Interindividual variability in antidepressant response has stimulated interest in precision psychiatry approaches.

Potential Applications:

- Genetic biomarkers to predict treatment response.
- Neuroimaging-based assessment of brain circuit abnormalities.
- Identification of inflammatory and neurochemical biomarkers.
- Individualized drug selection and dose optimization through pharmacogenomic testing.

Expected Benefits:

- Improved treatment efficacy.
- Reduced adverse effects.
- Faster achievement of remission.

4.2.2 Novel Receptor Modulators

Emerging antidepressant research is focused on selectively targeting receptor systems implicated in mood regulation and neuroplasticity.

Serotonin Receptor Modulators

- 5-HT7 receptor antagonists show promise in improving mood, cognition, and circadian rhythm regulation.

Glutamatergic Modulators

- AMPA receptor potentiators may enhance synaptic plasticity and antidepressant responses.
- Metabotropic glutamate receptor (mGluR) modulators are being investigated as alternatives to conventional antidepressants.

Triple Reuptake Inhibitors (TRIs)

- Simultaneously inhibit serotonin, norepinephrine, and dopamine reuptake.
- Aim to address a broader range of depressive symptoms, including motivational and cognitive deficits.

4.2.3 Neurostimulation Techniques

Neuromodulation therapies are increasingly utilized for patients with treatment-resistant depression.

Transcranial Magnetic Stimulation (TMS)

- Noninvasive magnetic stimulation targeting the dorsolateral prefrontal cortex.
- Improves neural connectivity and mood regulation.

Electroconvulsive Therapy (ECT)

- Remains one of the most effective interventions for severe depression.
- Particularly beneficial in psychotic depression, catatonia, and treatment-resistant cases.

Deep Brain Stimulation (DBS)

- Involves surgical implantation of electrodes into specific brain regions.
- Currently under investigation for refractory depression and severe mood disorders.

4.2.4 Psychedelic-Assisted Therapy

Psychedelic compounds have recently gained significant attention as potential rapid-acting antidepressants.

Psilocybin

- Primarily acts through serotonin 5-HT2A receptor modulation.
- Produces sustained improvements in depressive symptoms when combined with psychotherapy.

MDMA

- Enhances serotonin, dopamine, and norepinephrine release.
- Facilitates emotional processing and therapeutic engagement.

Potential Advantages:

- Rapid symptom relief.
- Enhancement of neuroplasticity.
- Long-lasting therapeutic effects following limited treatment sessions.

V. CONCLUSION

Depression is a multifactorial, heterogeneous disorder with dysregulation of neurotransmitters and receptor changes as etiologic factors. The serotonergic, noradrenergic, dopaminergic, and glutamatergic

neurotransmitter systems are key to mood regulation, and their dysregulation forms the basis of depression pathophysiology. All available pharmacotherapies such as SSRIs, SNRIs, NRIs, and atypical antidepressants share monoaminergic system targeting to some extent, but new therapies such as NMDA receptor antagonists and psychedelic-assisted therapy are on the horizon, particularly for treatment-resistant depression.

Pharmacological and neuroscientific progress continues to propel our innovation in antidepressant therapy. The discovery of new receptor modulators, neurostimulation methods, and personalized medicine strategies is full of promise for enhancing the efficacy and treatment outcomes. Greater knowledge of neurotransmitter-receptor interaction has the potential to lead to more effective, targeted, and fast-acting antidepressant treatments, reshaping the future of mental health treatment.

REFERENCES

[1] Albert, P. R., & Benkelfat, C. (2013). The neurobiology of depression—Revisiting the serotonin hypothesis. Current Opinion in Neurobiology, 23(3), 383–390.

[2] Anacker, C., & Hen, R. (2017). Adult hippocampal neurogenesis and cognitive flexibility—Linking memory and mood. Nature Reviews Neuroscience, 18(6), 335–346.

[3] Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews, 64(2), 238–258.

[4] Castrén, E. (2005). Is mood chemistry? Nature Reviews Neuroscience, 6(3), 241–246.

[5] Castrén, E., & Monteggia, L. M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. Neuropsychopharmacology, 46(1), 1–12.

[6] Cryan, J. F., & Leonard, B. E. (2010). Depression: From psychopathology to pharmacotherapy. Karger Publishers.

[7] Duman, R. S. (2014). Pathophysiology of depression and innovative treatments. Dialogues in Clinical Neuroscience, 16(1), 11–27.

[8] Duman, R. S., & Voleti, B. (2012). Signaling pathways underlying the pathophysiology and treatment of depression. Neuroscience & Biobehavioral Reviews, 36(9), 2085–2096.

[9] Fava, M., & Kendler, K. S. (2000). Major depressive disorder. Neuron, 28(2), 335–341.

[10] Fries, G. R., Saldana, V. A., Finnstein, J., & Rein, T. (2023). Molecular pathways of major depressive disorder converge on the synapse. Molecular Psychiatry, 28(1), 284–297.

[11] Harmer, C. J. (2008). Serotonin and emotional processing. Current Opinion in Pharmacology, 8(1), 41–46.

[12] Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology, 29(10), 1765–1781.

[13] Heninger, G. R., Delgado, P. L., & Charney, D. S. (1996). The revised monoamine theory of depression. American Journal of Psychiatry, 153(2), 151–162.

[14] Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019). Ketamine: A paradigm shift for depression research and treatment. Neuron, 101(5), 774–778.

[15] Liston, C., McEwen, B. S., & Casey, B. J. (2009). Psychosocial stress reversibly disrupts prefrontal processing and attentional control. Proceedings of the National Academy of Sciences, 106(3), 912–917.

[16] Maeng, S., & Zarate, C. A. (2007). The role of glutamate in mood disorders. Current Psychiatry Reports, 9(6), 467–474.

[17] Mann, J. J. (2013). The serotonergic system in mood disorders and suicidal behaviour. Philosophical Transactions of the Royal Society B, 368(1615), 20120537.

[18] McEwen, B. S. (2007). Physiology and neurobiology of stress and adaptation. Physiological Reviews, 87(3), 873–904.

[19] Menke, A. (2019). Is the HPA axis as target for depression outdated? Frontiers in Psychiatry, 10, 101.

[20] Monteggia, L. M., & Zarate, C. (2015). Antidepressant actions of ketamine. Molecular Psychiatry, 20(6), 654–656.

[21] Nestler, E. J. (2015). Role of the brain's reward circuitry in depression. Biological Psychiatry, 78(9), 599–601.

[22] Otte, C., Gold, S. M., Penninx, B. W., et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2, 16065.
[23] Parekh, P. K., Johnson, S. B., & Liston, C. (2022). Synaptic mechanisms regulating mood state transitions in depression. Annual Review of Neuroscience, 45, 581–601.
[24] Price, J. L., & Drevets, W. C. (2010). Neurocircuitry of mood disorders. Neuropsychopharmacology, 35(1), 192–216.
[25] Ressler, K. J., & Mayberg, H. S. (2007). Targeting abnormal neural circuits in mood and anxiety disorders. Nature Neuroscience, 10(9), 1116–1124.
[26] Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nature Reviews Neuroscience, 14(9), 609–625.
[27] Sanacora, G., Treccani, G., & Popoli, M. (2012). Towards a glutamate hypothesis of depression. Neuropharmacology, 62(1), 63–77.
[28] Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders. American Journal of Psychiatry, 122(5), 509–522.
[29] Sharp, T., & Cowen, P. J. (2011). 5-HT and depression: Is the glass half-full? Current Opinion in Pharmacology, 11(1), 45–51.
[30] Tye, K. M. (2018). Neural circuit motifs in valence processing. Neuron, 100(2), 436–452.
[31] Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016). Integrating neuroimmune systems in the neurobiology of depression. Nature Reviews Neuroscience, 17(8), 497–511.
[32] Yang, Y., Cui, Y., Sang, K., et al. (2018). Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature, 554(7692), 317–322.
[33] Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017). The role of 5-HT receptors in depression. Molecular Brain, 10(1), 28.
[34] Zarate, C. A., Machado-Vieira, R., & Henter, I. D. (2016). Novel glutamatergic agents for major depressive disorder. Current Psychiatry Reports, 18(3), 1–11.
[35] Pannu, A., & Goyal, R. K. (2025). The potential role of dopamine pathways in the pathophysiology of depression: Current advances and future aspects. CNS & Neurological Disorders - Drug Targets, 24(5), 340–352.